From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer
Chemical Biology & Drug Design · 2026-06 · 107 (6)
DOI: 10.1111/cbdd.70320 ↗At a glance
Journal article in Chemical Biology & Drug Design, published online on 2026-05-28. Written by Sandra Ferreira and 11 co-authors. Institution: CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal. Major MEDLINE topics: Amino Acid Oxidoreductases, Antineoplastic Agents, Thiazolidines, Enzyme Inhibitors. 60 references. Funded by: Fundação para a Ciência e a Tecnologia, Universidade Lusófona/ILIND, National Research Foundation of Ukraine.
Abstract (original language)
Lysyl Oxidases (LOXs) catalyse elastin and collagen cross‐linking in the extracellular matrix and have been implicated in cancer cell progression and metastases, particularly in breast cancer. In this study, we sought small‐molecule inhibitors of LOXL2 using a library of 4‐thiazolidones supported by molecular docking. Five candidates were prioritised, with Les 5740 displaying the highest LOXL2 inhibitory activity (IC 50 of 27 μM). Although Les 5740 showed low cytotoxicity in various cancer and normal‐like cell lines, the triple‐negative breast cancer (TNBC) cell line MDA‐MB‐231 showed increased susceptibility to this molecule. Les 5740 did not induce DNA damage in mammary cells. At 30 μM, it increased TNBC cells' necrosis. The impact of a non‐toxic concentration of Les 5740 (5 μM) on TNBC cell motility was evaluated. Les 5740 reduced 2D chemoinvasion and altered cell morphology. These findings are consistent with a potential reduction in extracellular matrix stiffness as a consequence of LOXL2 inhibition. Les 5740 mildly inhibited tubulin polymerisation, supporting a multi‐target profile. Overall, Les 5740 should be viewed as a starting scaffold with LOXL2 inhibitory activity and broader cellular effects, motivating optimisation toward more potent and selective LOXL2 inhibitors for breast cancer therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal.
- Dpto. de Ciencias Biomédicas (Farmacología), Universidad de Alcala, Alcalá de Henares, Madrid, España.
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
- Molecular Design Center, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
- Department of Organic Chemistry, Medical University of Lublin, Lublin, Poland.
- Department of Biotechnology and Cell Biology, University of Information Technology and Management in Rzeszow, Rzeszow, Poland.
ORCID profiles: Roman Lesyk, Daniel J V A Dos Santos, João G Costa
Funding
- Fundação para a Ciência e a Tecnologia
- Universidade Lusófona/ILIND
- National Research Foundation of Ukraine
- Universidade Lusófona de Humanidades e Tecnologias
Cite
APA
Ferreira, S., Santos, B., Tavares, M., Holota, S., Khylyuk, D., Lesyk, R., Finyuk, N., Dos Santos, D. J. V. A., Díaz-Lanza, A. M., Costa, J. G., Saraiva, N., & Fernandes, A. S. (2026). From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70320
Vancouver
Ferreira S, Santos B, Tavares M, Holota S, Khylyuk D, Lesyk R, et al. From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70320
BibTeX
@article{Ferreira2026,
author = {Ferreira, Sandra and Santos, Beatriz and Tavares, Matilde and Holota, Serhii and Khylyuk, Dmytro and Lesyk, Roman and Finyuk, Natalia and Dos Santos, Daniel J V A and Díaz-Lanza, Ana M and Costa, João G and Saraiva, Nuno and Fernandes, Ana S},
title = {From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {6},
doi = {10.1111/cbdd.70320}
}
EUVIMED